Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rHIgM12B7
- Development stage
- Phase 1
- Lead developer
- Mayo Clinic
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
rHIgM12B7 is a recombinant form of the monoclonal IgM antibody M12 isolated from a Waldenstrom macroglobulinaemia patient with potential immunomodulating activity. It functions as a B7-DC cross-linking agent, targeting programmed cell death 1 ligand 2.
- Other names
- B7-DC cross-linking antibody rHIgM12B7B-7-DC cross-linking antibody rHIgM12B7B 7-DC cross-linking antibody rHIgM12B7recombinant form of the monoclonal IgM antibody M12
02
Targets
PDCD1LG2 (Programmed cell death 1 ligand 2)
Beyond the preview
Go deeper on rHIgM12B7.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rHIgM12B7.